Abiopharma

🔍 Giordano Natasha (Director)

Company: ORAGENICS INC (OGEN)

Report Date: 2025-12-11

Detailed Transactions and Holdings:

• Acquired 38,320 shares of Non-Employee Director Option (Right to Buy) at $1.03 per share (Derivative)
  Date: 2025-12-11 | Code: A | Expires: 2035-12-11 | Exercise: 2025-12-11 | equity_swap_involved: 0 | shares_owned_after: 38,320.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Acquired 125,000 shares of Non-Employee Director Option (Right to Buy) at $0.93 per share (Derivative)
  Date: 2025-12-11 | Code: A | Expires: 2035-12-11 | Exercise: 2025-12-11 | equity_swap_involved: 0 | shares_owned_after: 125,000.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2, F2

Footnotes:

• F1: Represents an initial equity award upon appointment to the Company's board of directors (the "Board") of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan that vests immediately. The option exercise price is the Company's closing price on the date immediately prior to the reporting person's appointment to the Company's Board. The Board granted the options on December 11, 2025.
• F2: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant.